Article

Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.

Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois, USA.
American Journal of Ophthalmology (Impact Factor: 3.63). 02/2006; 141(1):200-1. DOI: 10.1016/j.ajo.2005.07.053
Source: PubMed

ABSTRACT To report the changes and trends in intraocular pressures (IOP) following intravitreal injection of Pegaptanib (Macugen) for the treatment of exudative age-related macular degeneration.
Retrospective chart review.
Review of 79 patients who underwent 122 consecutive Pegaptanib injections. Analysis of the short-term effect of Pegaptanib injections on IOP was performed.
Baseline mean IOP was 15.73 +/- 3.41 mm Hg (mean +/- standard deviation) with a range of 9 to 27 mm Hg. Postinjection mean IOP was 24.47 +/- 6.29 mm Hg with a range of 8 to 36 mm Hg. Mean IOP change from baseline to roughly 30 minutes after Pegaptanib injection was 8.74 +/- 7.23 mm Hg. At the 5- to 7-day follow-up visit, IOP had normalized.
Pegaptanib injection in this limited series seems to be safe from an IOP standpoint in the short-term. IOP monitoring postinjection may not be necessary.

0 Bookmarks
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To report the immediate changes of intraocular (IOP) pressure after an intravitreal injection of 2.5mg (0.1 ml) of bevacizumab. Prospective, non-controlled, interventional case series of 45 patients undergoing intravitreal injection of 2.5mg (0.1 mL) of bevacizumab for a variety of retinal disorders. IOP was measured with a Goldmann tonometer at baseline, immediately after, 30 minutes and one day after injection in all of the cases. The main outcome measured was the IOP immediately after injection. At baseline the mean IOP was 16.6±2.8mm Hg (range, 10-24 mm Hg; median, 16 mm Hg; 25(th) percentile, 14 mm Hg and 75(th) percentile, 18 mm Hg). IOP rose to 53.9±18.2mm Hg (range, 16-78 mm Hg, median, 54 mm Hg; 25(th) percentile, 40 mm Hg and 75(th) percentile, 70 mm Hg; p<0.001) immediately after the injection. After 30 minutes, the IOP normalized but was still higher than baseline with a mean of 19.8±5.2 mm Hg (range, 10-36 mm Hg; median,18 mm Hg; 25(th) percentile,16 mm Hg and 75(th) percentile, 24 mm Hg; P<.01). At 24 hours the IOP was 15.7±3.1 mm Hg (range,10-24 mm Hg; median, 16 mm Hg; 25(th) percentile,14 mm Hg and 75(th) percentile,18 mm Hg; p>0.05). An intravitreal injection of 2.5mg (0.1 ml) of bevacizumab causes a transient elevation of IOP that tends to return to normal 30 minutes later.
    Archivos de la Sociedad Espanola de Oftalmologia 11/2010; 85(11):364-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: To review recent literature regarding ocular hypertension following intravitreal antivascular endothelial growth factors (anti-VEGF). Method: An electronic literature search was performed using MEDLINE, OVID, and PubMed. Key search terms were elevated IOP, anti-VEGF, sustained IOP elevation in anti-VEGF, chronic intraocular pressure elevation in anti-VEGF, high IOP with anti-VEGF, acute elevation in intraocular pressure with anti-VEGF, glaucoma and anti-VEGF. Result: Transient elevation of intraocular pressure after intravitreal anti-VEGF injection is due to temporary increase in volume, and the acute spike generally does not affect a healthy eye. Caution should be taken in a glaucomatous eye, and pretreatment with an IOP-lowering medication is recommended. Persistent elevation of intraocular pressure is more common than previously thought and may be correlated to several factors including increased number of intravitreal injections. Conclusion: Persistent ocular hypertension may be associated with intravitreal anti-VEGF injections. Physicians should be aware of this condition and monitor their patients for persistent ocular hypertension, especially in eyes with preexisting glaucoma. Prompt diagnosis and treatment can prevent potential loss of vision.
    Seminars in ophthalmology 04/2013; · 1.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Intravitreal ranibizumab and pegaptanib are registered for neovascular age-related macular degeneration. No formal safety study has been conducted for intravitreal bevacizumab. These anti-vascular endothelial growth factor (anti-VEGF) drugs are being used on a large scale in daily practice for different ocular diseases. The objective of the present study was to systematically assess and compare the incidences of adverse events of anti-VEGFs. METHODS: A systematic search was conducted in April 2009 with no date restrictions in PubMed, Embase, Toxline, and the Cochrane library. We used the terms pegaptanib, bevacizumab, ranibizumab, intravitreal, and specific and general terms for adverse events. Studies describing adverse events after anti-VEGF injections and the official safety data were included. RESULTS: Two hundred and seventy-eight articles were included, and the incidences of adverse events were calculated separately for effect, safety, and specific side effect studies. The incidences of serious ocular and nonocular adverse events were approximately below 1 per 100 injections for intravitreal bevacizumab, intravitreal ranibizumab, and intravitreal pegaptanib. Most mild ocular adverse events were below 5 per 100 injections. CONCLUSION: The reported rates of serious adverse events were low after anti-VEGF injections. There is no sufficient evidence to conclude that there is a difference in incidences between the anti-VEGFs.
    Retina (Philadelphia, Pa.) 07/2011; 31(8):1449-69. · 2.93 Impact Factor